Presentation is loading. Please wait.

Presentation is loading. Please wait.

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

Published byNicolo Testa Modified over 5 years ago

Similar presentations

Presentation on theme: "Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A"— Presentation transcript:

1 Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study 
Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A. David Burden, MD, Michael Rissler, PhD, Christian Sieder, PhD, Roberto Orsenigo, MD, Kamel Chaouche-Teyara, PhD  Journal of the American Academy of Dermatology  Volume 80, Issue 5, Pages (May 2019) DOI: /j.jaad Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 2PRECISE study design and patient disposition. This was a phase 3b multicenter, randomized, double-blind, placebo-controlled, parallel-group study. AE, Adverse event; TP2, treatment period 2. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Proportion of subjects (full analysis set 1, all patients, last observation carried forward) achieving a 75% improvement from baseline in the Palmoplantar Psoriasis Area Severity Index score (PPPASI75) through week 16. The primary end point was not met, but clinical benefit was observed with secukinumab, 300 mg, with 26.6% of subjects achieving PPPASI75 at week 16. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

4 Fig 3 Improvements in the rate of achievement of a 75% improvement from baseline in the Palmoplantar Psoriasis Area Severity Index (PPPASI75) with secukinumab were observed to continue to week 52. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2019 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A"

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial  Diamant.
Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH 
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study 
ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,

ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Thomas B. Casale, MD, Patrick H. Win, MD, Jonathan A

Thomas B. Casale, MD, Patrick H. Win, MD, Jonathan A
Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 
ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,

ATX-101 for reduction of submental fat: A phase III randomized controlled trial  Shannon Humphrey, MD, Jonathan Sykes, MD, Jonathan Kantor, MD, MSCE, MA,
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.
Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.
Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial  Catherine Maari, MD, FRCPC, Philippe Marchessault,
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.
Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial  William Tuong,

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial  William Tuong,
Pharmacy costs of specialty medications for plaque psoriasis in the United States  Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Pharmacy costs of specialty medications for plaque psoriasis in the United States  Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,
Smoking and risk of psoriasis: A nationwide cohort study

Smoking and risk of psoriasis: A nationwide cohort study

Similar presentations

Ads by Google